By: John Tuddenham, Masashi Fujita, Anthony Khairallah, Claire Harbison, Silas Maniatis, Aidan Daly, Julie A Schneider, Andrew Teich, Jean Paul G Vonsattel, Peter A Sims, Wassim Elyaman, Elizab
Abstract Development of therapeutic approaches that target specific microglia responses in amyotrophic lateral sclerosis (ALS) is crucial due to the involvement of microglia in ALS progression.